Capillary leak syndrome in a patient treated with interleukin 2 fusion toxin for cutaneous T-cell lymphoma [1]

Journal of the American Academy of Dermatology

Volumn 43, Issue 2 I, 2000, Pages 323-324

  Railan, D ^a   Fivenson, D P ^a   Wittenberg, G ^a  

^a HENRY FORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DENILEUKIN DIFITOX; DENILEUKIN DIFTITOX; UNCLASSIFIED DRUG;

AGED; CAPILLARY LEAK SYNDROME; CASE REPORT; DRUG EFFICACY; EDEMA; ERYTHRODERMA; FLUID RETENTION; HUMAN; HYPOTENSION; LETTER; MALE; PLEURA EFFUSION; PRIORITY JOURNAL; RESPIRATORY DISTRESS; T CELL LYMPHOMA;

EID: 0033855404     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1067/mjd.2000.106373     Document Type: Letter

References (5)

1. Interleukin-2 fusion protein: An investigational therapy for interleukin-2 receptor expressing malignancies
2. Role of nitric oxide in IL-2 therapy-induced capillary leak syndrome
3. The systemic capillary leak syndrome: Appearance of interleukin-2 receptor positive cells during attacks
4. Activation of the complement system during immunotherapy of cancer with interleukin-2: A possible explanation of the capillary leak syndrome
5. Phase Ib trial of pentoxifylline and ciprofloxacin in patients treated with interleukin-2 and lymphokine-activated killer cell therapy for metastatic renal cell carcinoma